ProCE Banner Activity

LIBRETTO-431: Randomized Phase III Trial of First-line Selpercatinib vs Chemotherapy Plus Pembrolizumab in RET Fusion‒Positive NSCLC

Conference Coverage
Slideset

In the phase III LIBRETTO-431 trial, first-line selpercatinib significantly improved median PFS vs chemotherapy plus pembrolizumab (HR: 0.465), meeting the primary endpoint and supporting selpercatinib as a standard of care for patients with RET fusion‒positive NSCLC.

Released: October 24, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc